A novel palmitoylethanolamide formulation improves hyperalgesia and red cell instability in murine sickle cell disease

Blood Vessels Thrombosis & Hemostasis 2026 Open access

Read full text
Authors: Donovan Alexander Argueta, Natalie R. Garcia, Alex Mabou Tagne, Daniele Piomelli, Kalpna Gupta
DOI: 10.1016/j.bvth.2026.100136
Cited by: 0
References: 26

Abstract

1. Oral, water-dispersible palmitoylethanolamide is rapidly bioavailable and improves hematological markers of sickle cell disease. 2. Oral palmitoylethanolamide reduces inflammation as well as chronic and acute hyperalgesia in sickle cell disease.

Fields of Study & Subjects

Hemoglobinopathies and Related Disorders Folate and B Vitamins Research Cassava research and cyanide

Publication details

Journal / source
Blood Vessels Thrombosis & Hemostasis
Volume
3
Issue
1
Pages
100136–100136
Publication date
5 January 2026
Language
EN